The study’s authors concluded that, at the median follow-up of 23 months, the data demonstrated comparable progression-free survival, sustained response, and overall survival between both the biosimilar and the reference product.
At the American Society of Hematology’s annual meeting in San Diego, California, that took place December 1-4, 2018, researchers presented data from an ongoing randomized, double-blind trial that compared the efficacy of CT-P10 (Truxima)—a newly FDA-approved rituximab biosimilar—with reference rituximab (Rituxan) in patients with previously untreated advanced follicular lymphoma.
The study enrolled 140 patients, 124 patients of whom completed the full 8 cycles of rituximab, cyclophosphamide, vincristine, prednisone (R-CVP) induction therapy. In total, 122 patients who showed response during the induction period (62 patients in the CT-P10 treatment arm and 60 patients in the reference arm) then moved on to the maintenance period, during which 12 cycles of rituximab monotherapy were administered at intervals of 2 months.
Efficacy was determined based on outcomes including progression free survival, duration of response, and overall survival (OS). The updated safety profile of CT-P10 compared with reference rituximab in advanced follicular lymphoma was also assessed. The study was designed to continue until death or up to 3 years from the randomized date of the last patient.
At the time of the cutoff date, the median follow-up was 23 months (range, 0.5-34) in the CT-P10 group and 22 months (range, 0.2-33) in the reference rituximab group. The rates of relapse, disease progression, or death from any cause were 22.9% and 24.3% for the CT-P10 and reference rituximab groups, respectively.
As for sustained response, the proportion of patients who showed relapse or disease progression after previously achieving overall response was 19.4% in CT-P10 arm and 21.3% in the reference arm. Notably, there was no statistically significant difference in OS between either group with a 2-year OS of 93.2% for CT-P10 patients and 95.3% in reference rituximab patients.
Furthermore, “The updated safety results did not reveal any new trends or new signals noted in the patients treated with CT-P10,” a Celltrion representative told The Center for Biosimilars® in an email.
The study’s authors concluded that, at the median follow-up of 23 months, the data demonstrated comparable progression-free survival, sustained response, and OS between both the biosimilar and the reference product.
CT-P10 was approved by the FDA on November 28, 2018, under the brand name Truxima, though a launch date has yet to be disclosed. “Celltrion and Teva Pharmaceutical Industries entered into an exclusive partnership in October 2016 to commercialize Truxima in the US and Canada. Teva and Celltrion have reached a settlement agreement with Genentech, including entry terms. The terms and conditions of that agreement are confidential at this time,” noted Woosung Kee, CEO of Celltrion.
Reference
Won-Seog, K, Buske C, Kwak L, et al.Similar efficacy and safety of CT-P10 and reference rituximab in patients with advanced stage follicular lymphoma: updated phase III study results. Presented at the 60th Annual Meeting and Exposition of the American Society of Hematology; December 1-4, 2018; San Diego, California. Abstract 1616. ash.confex.com/ash/2018/webprogram/Paper112716.html.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.